Oncotarget

Research Papers:

Intracellular activation of EGFR by fatty acid synthase dependent palmitoylation

Lakshmi Reddy Bollu _, Rajashekhara Reddy Katreddy, Alicia Marie Blessing, Nguyen Pham, Baohui Zheng, Xu Wu and Zhang Weihua

PDF  |  HTML  |  Supplementary Files  |  How to cite

Oncotarget. 2015; 6:34992-35003. https://doi.org/10.18632/oncotarget.5252

Metrics: PDF 2358 views  |   HTML 3038 views  |   ?  


Abstract

Lakshmi Reddy Bollu1, Rajashekhara Reddy Katreddy1, Alicia Marie Blessing1, Nguyen Pham1, Baohui Zheng2, Xu Wu2, Zhang Weihua1

1Department of Biology and Biochemistry, College of Natural Sciences and Mathematics, University of Houston, Houston, Texas, USA

2Cutaneous Biology Research Center, Massachusetts General Hospital, Harvard Medical School, Charlestown, Massachusetts, USA

Correspondence to:

Zhang Weihua, e-mail: [email protected]

Keywords: EGFR, fatty acid synthase, palmitoylation, palmitoyl transferases, cancer

Received: May 28, 2015     Accepted: August 31, 2015     Published: September 12, 2015

ABSTRACT

Epidermal growth factor receptor (EGFR) is an oncogenic receptor tyrosine kinase. Canonically, the tyrosine kinase activity of EGFR is regulated by its extracellular ligands. However, ligand-independent activation of EGFR exists in certain cancer cells, and the underlying mechanism remains to be defined. In this study, using PC3 and A549 cells as a model, we have found that, in the absence of extracellular ligands, a subpopulation of EGFR is constitutively active, which is needed for maintaining cell proliferation. Furthermore, we have found that fatty acid synthase (FASN)-dependent palmitoylation of EGFR is required for EGFR dimerization and kinase activation. Inhibition of FASN or palmitoyl acyltransferases reduced the activity and down-regulated the levels of EGFR, and sensitized cancer cells to EGFR tyrosine kinase inhibitors. It is concluded that EGFR can be activated intracellularly by FASN-dependent palmitoylation. This mechanism may serve as a new target for improving EGFR-based cancer therapy.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 5252